Noumed contracts reach AUD 232m as in-house shift nears

Noumed Pharmaceuticals has Australian over-the-counter, or OTC, medicine supply contracts worth AUD 232 million, approximately Rs 1,506 crore, following renewals announced in July and August 2026. Sai Parenterals Limited plans to shift largely third-party-sourced volume to its Indian plants and an Adelaide facility expected to begin commercial supply around April 2027.

How large is Noumed’s Australian OTC contracted supply?

Noumed’s disclosed contracted Australian OTC supply totals AUD 232 million, approximately Rs 1,506 crore. The total combines a 7.5-year agreement worth AUD 202 million, renewed on 1 July 2026, with a three-year agreement worth AUD 30 million, approximately Rs 204 crore, renewed on 25 August 2026 with one of Australia’s leading pharmacy chains.

The agreements provide for new products and line extensions during their respective terms, meaning the disclosed value covers more than an existing set of supplied items. Noumed was acquired in November 2025 and operates in Australia and New Zealand, where it has 15 exclusive long-term supply agreements covering 491 stock-keeping units, or SKUs. More than 50% of Sai’s consolidated revenue is contracted under long-term regulated-market agreements.

The AUD 232 million figure is contracted supply value rather than reported revenue for a specified period. The agreements also have materially different durations, with the larger AUD 202 million contract extending for 7.5 years and the AUD 30 million renewal lasting three years. Sai did not disclose annual revenue allocations, delivery schedules, product-level pricing or the profitability of either agreement in its 1 November 2026 release.

How will Noumed move supply from third-party manufacturers to in-house production?

Noumed currently sources most volumes under these Australian OTC contracts from third-party manufacturers, and Sai plans progressively to produce them internally. Management’s stated aim is to convert the distribution margin on this volume into a manufacturing margin as the Adelaide site is commissioned and capacity in India expands.

The Adelaide facility is due to begin operations in January 2027, with commercial supply expected from around April 2027. Until then, Sai said it will support Noumed with bulk tablets from India. January 2027 is the planned operational start, while around April 2027 is the stated timing for commercial supply, leaving a further commissioning phase before the site is expected to supply customers.

Indian production capacity is also being expanded to support the shift. Sai completed the Unit III expansion at Bhongir, lifting monthly capacity by 81% from 85.5 million units to 155 million units. Output is planned to ramp up from Q4FY27, with most of the additional volume intended for Australia and New Zealand. The added lines include ointment manufacturing and automated tube filling, capsule blending and filling, and liquid-oral manufacturing and filling.

What does Australia contribute to Sai’s current export mix?

Australia accounted for 76% of Sai’s export revenue in Q2FY27, down from 83% in Q1FY27. Management said the Q1 share was elevated because Sai supplied additional volumes to Noumed after third-party contract manufacturers fell short, while management plans export capacity broadly on a 70:30 basis between Australia and other markets.

Australia’s share therefore fell by 7 percentage points quarter on quarter, even as Sai’s consolidated revenue increased 9.0% to Rs 196.1 crore in Q2FY27 from Rs 179.9 crore in Q1FY27. The release does not provide Noumed’s standalone sales or the Australian OTC contracts’ contribution to that Rs 196.1 crore, so the disclosed group figures cannot assign a current revenue amount to the two renewed agreements.

For H1FY27, Sai reported consolidated revenue of Rs 376.0 crore, about 50% of its Rs 750 crore FY27 revenue target. The company said this was ahead of its guided 45:55 revenue phasing between the first and second halves. However, it also cautioned that year-on-year comparison is not like-for-like because Q2FY27 and H1FY27 included a full quarter of Noumed, while Noumed was consolidated only from 12 November 2025 in the prior-year periods.

What milestones could affect Noumed’s supply transition?

The disclosed milestones are the Q4FY27 output ramp at Unit III, the Adelaide facility’s January 2027 operating start and its expected commercial supply from around April 2027. These dates matter because Sai’s plan depends on replacing third-party production with output from its own facilities, rather than retaining distribution arrangements for the contracted Australian volumes.

Sai’s wider manufacturing programme includes a critical-care injectable facility being built through Saicriti Pharma, targeted for completion in July 2027. That project is separate from the oral and OTC supply transition described for Adelaide and Unit III, but it adds to the group’s capital programme. On completion, Saicriti is intended to take injectable capacity to about 154.66 million units and replace Units I and II at Jeedimetla.

The company also consolidated group research and development at Sai Prathyak Laboratories after completing a 60% acquisition on 5 October 2026 for Rs 15 crore. Sai Prathyak has 28 research scientists, 174 molecules and 285 SKUs across critical care and oncology, and is expected to begin taking external contract development and manufacturing organisation, or CDMO, contracts over the next two quarters, with revenue expected from FY28. These activities are not identified as part of the Australian OTC contracts, but form part of Sai’s broader manufacturing and development expansion.

Conclusion

Noumed’s AUD 232 million, approximately Rs 1,506 crore, Australian OTC contract base provides a disclosed multi-year supply pipeline across two renewed agreements. The central operational change is not the contract renewals alone, but Sai’s plan to move largely third-party-made volume into Adelaide and Indian facilities, which management says would change the economics from distribution to manufacturing margin.

The next milestones are Unit III’s Q4FY27 output ramp, Adelaide’s planned January 2027 start of operations and commercial supply expected around April 2027. Readers should watch whether the planned in-house transition occurs on that timetable, because Sai has not disclosed contract-by-contract production transfer dates, annual delivery volumes or the margins attached to the Australian agreements.